Alpha-L-rhamnosidase mutant capable of efficiently converting naringin and application of alpha-L-rhamnosidase mutant
By site-directed mutagenesis of key amino acid sites of α-L-rhamnosidase, a mutant that efficiently converts naringin was constructed, solving the problems of low enzyme activity and insufficient conversion efficiency in existing enzymes, and realizing the efficient biomanufacturing of purine.
Patent Information
- Application Number
- CN202511886952.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-12-15
- Publication Date
- 2026-01-23
AI Technical Summary
Existing α-L-rhamnosidase exhibits low enzyme activity and insufficient conversion efficiency when catalyzing naringin, making it difficult to meet the needs of industrial production. There is also a lack of systematic modification targeting the key amino acids in the active site.
By using structure-guided targeted saturation mutations of the active site, site-directed mutagenesis was performed on key amino acid sites to construct α-L-rhamnosidase mutants F281W, T284M, and L343V, thereby improving catalytic efficiency and stability.
The mutant significantly improved the hydrolysis efficiency of naringin, generating purunine with better solubility and bioactivity, overcoming the insufficient catalytic performance of existing enzyme preparations in industrial applications, and maintaining high activity and stability under industrial conditions.
Smart Images

Figure CN121380028A_ABST
Abstract
Description
TECHNICAL FIELD
[0001] The present application relates to the technical field of genetic engineering and enzyme engineering, and particularly relates to a kind of high-efficiency conversion naringin α-L-rhamnosidase mutant and application thereof. BACKGROUND
[0002] α-L-rhamnosidase (EC 3.2.1.40) is a kind of glycoside hydrolase, mainly belonging to GH13, GH28, GH78 and GH106 family, which can specifically hydrolyze the terminal α-1,2, α-1,3, α-1,4 and α-1,6 glycosidic bond of polysaccharide or glycoside compound, release L-rhamnose, and produce new polysaccharide or glycoside compound, including hydrolysis of natural flavonoid glycoside compounds such as hesperidin, neohesperidin, naringin, rutin and astilbin, and the hydrolysis products are hesperetin monoglucoside, prunin, isoquercitrin and dihydroquercetin, etc. α-L-rhamnosidase can be applied to the removal of bitterness of citrus juice, improvement of beverage flavor and production of sweetener in food industry; α-L-rhamnosidase can also be applied to the preparation of various drugs and drug precursors in pharmaceutical industry; and in chemical industry, a-L-rhamnosidase can be used as a biological catalyst.
[0003] Naringin (4'-5,7'-trihydroxydihydroflavonol-7-rhamnose glucoside) is a kind of dihydroflavonoid compound, which is the main effective component of traditional Chinese medicine drynaria, bitter orange and other medicines. However, due to the poor solubility of naringin in water, its utilization rate is very low, which greatly limits its drug activity and application in the development of functional food. α-L-rhamnosidase can specifically hydrolyze naringin to generate prunin (naringenin-7-O-glucoside), which has one less rhamnoside than naringin, but has good solubility, and has good biological activities such as antiviral, antitumor, antioxidant, cholesterol reduction and blood sugar balance regulation, and is widely used in food, medicine and cosmetics fields. At present, prunin has very low content in nature, and it is difficult to obtain it on a large scale by extraction method, so the biological transformation of naringin with rich source and low price by using α-L-rhamnosidase has become the main way to prepare prunin.
[0004] However, the natural source or existing recombinant expressed alpha-L-rhamnosidase has low enzyme activity and insufficient conversion efficiency in catalyzing naringin hydrolysis, which is difficult to meet the demand of high catalytic efficiency in industrial production. The reasons for the above problems mainly include: the substrate specificity and catalytic rate of the natural enzyme to naringin are limited; the yield of part of the enzyme in the expression system is low or the stability is poor; the existing enzyme molecular modification research is less, and there is lack of systematic engineering modification of key residues in the active center. Although protein engineering techniques such as site-directed mutagenesis have been widely used to improve the catalytic performance of other glycoside hydrolases, in alpha-L-rhamnosidase, relevant research is still in its infancy, especially lacking rational design and mutation based on enzyme-substrate interaction mechanism and key amino acids in the active pocket.
[0005] Therefore, developing alpha-L-rhamnosidase mutants with high catalytic activity and high naringin conversion efficiency has become the key to promoting the development of enzyme production of prunin technology. Through structure-guided active center targeted saturation mutation, systematic modification of key amino acid sites affecting substrate binding and catalytic efficiency is expected to obtain mutant enzymes with significantly improved catalytic performance, thereby providing core catalysts for efficient and green biological manufacturing of prunin. SUMMARY
[0006] The purpose of the present application is to provide an alpha-L-rhamnosidase mutant with high efficiency in converting naringin and its application, in order to solve the problems existing in the prior art. The alpha-L-rhamnosidase mutant provided by the present application has significantly improved catalytic efficiency, while maintaining good pH stability, effectively solving the technical bottleneck of low catalytic efficiency of natural enzymes, providing a high-performance catalyst for green and efficient biological manufacturing of prunin, and having important industrial application value.
[0007] To achieve the above purpose, the present application provides the following solutions.
[0008] The present application provides an alpha-L-rhamnosidase mutant, whose amino acid sequence is any one of SEQ ID NO. 11-13.
[0009] The present application also provides a gene encoding the alpha-L-rhamnosidase mutant.
[0010] The present application also provides a recombinant vector comprising the gene.
[0011] The present application also provides an engineered bacterium comprising the recombinant vector.
[0012] Optionally, the engineered bacterium is a Pichia pastoris engineered bacterium.
[0013] The application also provides application of the alpha-L-rhamnosidase mutant, the gene, the recombinant carrier or the recombinant bacteria in improving catalytic efficiency of alpha-L-rhamnosidase.
[0014] Optionally, the catalytic efficiency of the alpha-L-rhamnosidase is improved to improve the efficiency of the alpha-L-rhamnosidase in catalyzing naringin to generate naringin-7-O-glucoside.
[0015] The application also provides application of the alpha-L-rhamnosidase mutant, the gene, the recombinant carrier or the recombinant bacteria in improving catalytic efficiency of alpha-L-rhamnosidase.
[0016] The application also provides a method for improving the production efficiency of naringin-7-O-glucoside, which comprises the process of using the alpha-L-rhamnosidase mutant to catalyze naringin to generate naringin-7-O-glucoside.
[0017] Optionally, the pH value of the catalysis is 5, and the reaction temperature is 60 DEG C.
[0018] The application discloses the following technical effects:
[0019] The alpha-L-rhamnosidase mutant provided by the application is obtained through structure-guided rational design and site-directed mutagenesis of key sites in the active center, and effectively solves the bottleneck problems of low catalytic activity and insufficient substrate conversion efficiency of the natural enzyme. Specifically, the specific enzyme activity of the mutants F281W, T284M and L343V is significantly improved compared with the wild type, the hydrolysis efficiency of naringin is greatly improved, naringin can be efficiently and specifically catalyzed to convert into prunin with better solubility and biological activity, and the defects of the existing enzyme preparation in the industrial application, such as insufficient catalytic performance, are overcome.
[0020] In addition, the mutants obtained in the application have improved pH stability and thermal stability while maintaining the optimum pH and temperature, which is beneficial to maintaining high activity under industrial catalytic conditions. Experimental data show that the catalytic efficiency (K cat / K m ) of the mutant T284M is improved by about 195.8% compared with the wild type, and the product generation rate of prunin is significantly improved under the condition of high-concentration substrate. Therefore, the mutant provides a catalyst with excellent performance for green and efficient biological manufacturing of prunin, and has important industrial application value. BRIEF DESCRIPTION OF DRAWINGS
[0021] In order to more clearly illustrate the technical solutions in the embodiments of the present application or the prior art, the accompanying drawings needed in the embodiments will be briefly introduced as follows. Obviously, the accompanying drawings in the following description only only some embodiments of the present application, and for those skilled in the art, other drawings can be obtained from these drawings without creative effort.
[0022] Figure 1 Figure 4 is a relative enzyme activity graph of wild type α-L-rhamnosidase and α-L-rhamnosidase mutants;
[0023] Figure 2 Figure 6 is a naringin liquid phase standard curve graph;
[0024] Figure 3 Figure 8 is a naringenin-7-O-glucoside liquid phase standard curve graph;
[0025] Figure 4 Figure 10 is a product yield graph of wild type α-L-rhamnosidase and mutant reaction 50 g / L naringin;
[0026] Figure 5 Figure 12 is a determination of the optimum pH of wild type α-L-rhamnosidase and mutant T284M enzyme;
[0027] Figure 6 Figure 14 is the effect of different pH values on the activity stability of wild type α-L-rhamnosidase and mutant T284M enzyme;
[0028] Figure 7 Figure 16 is a determination of the optimum temperature of wild type α-L-rhamnosidase and mutant T284M enzyme;
[0029] Figure 8 Figure 18 is the activity stability of wild type and mutant T284M enzyme at the optimum temperature. DETAILED DESCRIPTION
[0030] Various exemplary embodiments of the present application will now be described in detail, which should be considered to be illustrative of the application and should not be construed to limit the scope of the application. It should be understood that many variations and modifications of the application can be made while remaining within the scope of the application.
[0031] It should be understood that the terms used in the present application merely describe particular embodiments and are not intended to limit the present application. In addition, for the numerical ranges in the present application, it should be understood that each intermediate value between the upper limit and the lower limit of the range is specifically disclosed. Each smaller range between any stated value or stated range, and any other stated value or stated range within the stated range is also encompassed within the present application. The upper limit and the lower limit of these smaller ranges can be independently included or excluded from the range.
[0032] Unless otherwise indicated, all technical and scientific terms have the same meaning as those one of ordinary skill in the art of the disclosure would understand. Although preferred methods and materials are described, any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure. All documents mentioned herein are incorporated by reference to disclose and describe in full the methods and / or materials useful in connection to the documents. In case of conflict, the present document will control.
[0033] Many modifications and variations of the present disclosure described in the detailed description of the disclosure can be made by those skilled in the art without departing from the scope or spirit of the disclosure. Other implementations of the disclosure will be apparent to those skilled in the art from consideration of the specification and practice of the disclosure. The specification and examples of the disclosure are illustrative only.
[0034] As used herein, the terms "comprises", "comprising", "includes", "including", "has", "having", and the like are open-ended terms that are intended to permit but not limit the inclusion of elements or the number of elements, as well as the possibility that one or more other elements can be added or otherwise included.
[0035] Unless otherwise specified, the experimental methods used in the experiments involved in the present disclosure are conventional methods; the materials and reagents used in the examples of the present disclosure are commercially available biological experimental materials, unless otherwise specified.
[0036] Example 1 Construction of α-L-rhamnosidase mutants
[0037] In this example, based on the rational design strategy of conservation and stability analysis, the amino acid sites near the active center of wild-type α-L-rhamnosidase were systematically modified. This strategy starts from in-depth analysis of its molecular structure, and then specific single or multiple amino acid sites are subjected to site-directed mutagenesis, or local sequence regions are subjected to combinatorial mutagenesis, and then a mutant library is constructed, and the function of the mutant is evaluated by specific screening and selection methods. The present disclosure takes the α-L-rhamnosidase with the amino acid sequence shown in SEQ ID NO. 1 as the starting template, and the key sites are subjected to the following (a)-(e) single or multiple point combination mutations to obtain enzyme variants with optimized performance:
[0038] (a) R231L: the amino acid corresponding to site 248 on SEQ ID NO. 1 is mutated from arginine (R) to leucine (L);
[0039] (b) F281W: the amino acid corresponding to site 298 on SEQ ID NO. 1 is mutated from phenylalanine (F) to tryptophan (W);
[0040] (c) T284M: the amino acid corresponding to site 301 on SEQ ID NO. 1 is mutated from threonine (T) to methionine (M);
[0041] (d) L343V: the amino acid corresponding to position 360 on SEQ ID NO. 1 is mutated from Leucine (L) to Valine (V).
[0042] The sequence shown in SEQ ID NO. 1 is the amino acid sequence of wild-type a-L-rhamnosidase Rha, as follows:
[0043] MWSSWLLSALLATEALA VPYEEYILAPSSRDLAPASVRQVNGSVTNAAALTGAGGQATFNGVSSVTYDFGINVAGIVSVDVASASSESAFIGVTFTESSMWISNEACDATQDAGLDTPLWFAVGQGAGVYSVGKKYTRGAFRYMTVVSNTTATVSLNSVKINYTASPIQDLRAYTGYFHSSDELLNRIWYAGAYTLQLCSIDPTTGDALVGLGAITSSETITLPQTDKWWTNYTITNGSSTLTDGAKRDRLVWPGDMSIALESVAVSTEDLYSVRTALESLYALQKADGQLPYAGKPFYDTVSFTYHLHSLVGAASYYQYTGDRAWLTRYWGQYKKGVQWALSGVDSTGLANITASADWLRFGMGAHNIEANAILYYVLNDAISLAQSLNDNAPIRNWTATAARIKTVANELLWDDKNGLYTDNETTTLHPQDGNSWAVKANLTLSANQSAIISESLAARWGPYGAPAPEAGATVSPFIGGFELQAHYQAGQPDRALDLLRLQWGFMLDDPRMTNSTFIEGYSTDGSLVYAPYTNRPRVSHAHGWSTGPTSALTIYTAGLRVTGPAGATWLYKPQPGNLTQVEAGFSTRLGSFASSFSRSGGRYQELSFTTPNGTTGSVELGDVSGQLVSEGGVKVQLVGGKASGLQGGKWRLNV (the signal peptide is identified by underlining).
[0044] The gene sequence encoding wild-type a-L-rhamnosidase Rha is shown in SEQ ID NO. 2.
[0045] SEQ ID NO. 2:
[0046]
[0047] The coding gene of wild-type a-L-rhamnosidase shown in SEQ ID NO. 2 was inserted into plasmid pPIC9K to construct recombinant plasmid pPIC9K-Rha. The mutant enzyme recombinant expression vector was constructed using a site-directed mutagenesis kit with the recombinant plasmid pPIC9K-Rha as a template, and the specific steps were as follows:
[0048] (1) PCR amplification
[0049] According to the gene sequence of wild-type a-L-rhamnosidase and the mutation of the target site, the corresponding site-directed mutagenesis primers were designed, as shown in Table 1. For example, the corresponding site-directed mutagenesis primers for site-directed mutagenesis at position 248 were R231L-F and R231L-R. The recombinant plasmid pPIC9K-Rha was used as a template for PCR amplification to obtain a linear DNA fragment of the full plasmid length.
[0050] Table 1 Site-directed mutagenesis primers
[0051]
[0052] (2) Digestion of template plasmid DNA with Dpn I
[0053] 1 μL Dpn I was added to the PCR reaction solution obtained in step (1) and mixed gently, and reacted at 37°C for 1 hour to specifically degrade the original template plasmid with methylation.
[0054] (3) Self-circularization of PCR product
[0055] After purification of the digestion product obtained in step (2), in vitro self-ligation reaction was performed to circularize the complete plasmid. The ligation product was transformed into E. coli JM109 to obtain the corresponding recombinant E. coli, which was plated on a plate containing ampicillin sodium and cultured at 37°C overnight. Randomly selected clones were subjected to colony PCR identification and sequencing verification. The results showed that the recombinant expression vector containing the a-L-rhamnosidase mutant gene was successfully transformed into the expression host E. coli JM109. The bacterial solution with successful mutation verified by sequencing was added with glycerol and preserved in a -80°C refrigerator.
[0056] High-purity and high-concentration mutant plasmid was extracted from the correct strain, and linearized. The linearized DNA was transformed into Pichia pastoris GS115 competent cells by electroporation. The transformed cells were plated on a selection plate and cultured at 30°C for 2-4 days until single colonies appeared. Colony PCR was used to identify whether the target gene was successfully integrated into the Pichia pastoris genome, and positive recombinant yeast engineering bacteria were screened.
[0057] Example 2 Expression and purification of wild-type and mutant α-L-rhamnosidases
[0058] The Pichia pastoris recombinant strains containing wild-type and mutant α-L-rhamnosidases were respectively subjected to high-density fermentation under optimal conditions, and the promoter AOX1 was strongly induced by methanol to drive the high-efficiency expression of the target genes (wild-type or mutant α-L-rhamnosidase genes). After the expression was completed, the supernatant was collected by centrifugation to obtain the crude enzyme solutions of wild-type and mutant α-L-rhamnosidases, respectively.
[0059] After the crude enzyme was filtered by a 0.45 μm filter membrane, it was purified by a nickel column and eluted by a buffer solution containing 200 mM imidazole to obtain the pure enzymes of wild-type and mutant α-L-rhamnosidases, respectively.
[0060] Example 3 Determination of enzyme activity of wild-type and mutant α-L-rhamnosidases
[0061] Using naringin as the substrate: 950 μL of a 10 g / L naringin solution was prepared in a sodium phosphate buffer (50 mM, pH 5.0), 50 μL of the pure enzyme solution was added, and the reaction was carried out at 60 °C and 150 rpm for 30 min, followed by inactivation of the enzyme in a 100 °C boiling water bath for 5 min. The rhamnose content was determined by the DNS reagent. Under the optimal reaction conditions, the amount of enzyme required to produce 1 μmol of rhamnose per minute was defined as one enzyme activity unit (U).
[0062] The results of the determination of the relative enzyme activity of wild-type and mutant α-L-rhamnosidases are shown in Table 1. Figure 1 As shown in Table 1, the enzyme activity of the mutant α-L-rhamnosidases F281W, T284M and L343V was 1.68 times, 2.8 times and 1.4 times that of the wild-type enzyme, respectively, and the relative enzyme activity was greatly improved. The relative enzyme activity of other mutants did not increase or decreased to different degrees. The amino acid sequences of the mutant α-L-rhamnosidases F281W, T284M and L343V are shown in SEQ ID NO. 11-13, respectively.
[0063] SEQ ID NO. 11 (mutant α-L-rhamnosidase F281W):
[0064] MWSSWLLSALLATEALAVPYEEYILAPSSRDLAPASVRQVNGSVTNAAALTGAGGQATFNGVSSVTYDFGINVAGIVSVDVASASSESAFIGVTFTESSMWISNEACDATQDAGLDTPLWFAVGQGAGVYSVGKKYTRGAFRYMTVVSNTTATVSLNSVKINYTASPIQDLRAYTGYFHSSDELLNRIWYAGAYTLQLCSIDPTTGDALVGLGAITSSETITLPQTDKWWTNYTITNGSSTLTDGAKRDRLVWPGDMSIALESVAVSTEDLYSVRTALESLYALQKADGQLPYAGKPWYDTVSFTYHLHSLVGAASYYQYTGDRAWLTRYWGQYKKGVQWALSGVDSTGLANITASADWLRFGMGAHNIEANAILYYVLNDAISLAQSLNDNAPIRNWTATAARIKTVANELLWDDKNGLYTDNETTTLHPQDGNSWAVKANLTLSANQSAIISESLAARWGPYGAPAPEAGATVSPFIGGFELQAHYQAGQPDRALDLLRLQWGFMLDDPRMTNSTFIEGYSTDGSLVYAPYTNRPRVSHAHGWSTGPTSALTIYTAGLRVTGPAGATWLYKPQPGNLTQVEAGFSTRLGSFASSFSRSGGRYQELSFTTPNGTTGSVELGDVSGQLVSEGGVKVQLVGGKASGLQGGKWRLNV.
[0065] SEQ ID NO. 12 (a-L-rhamnosidase mutant T284M):
[0066] MWSSWLLSALLATEALAVPYEEYILAPSSRDLAPASVRQVNGSVTNAAALTGAGGQATFNGVSSVTYDFGINVAGIVSVDVASASSESAFIGVTFTESSMWISNEACDATQDAGLDTPLWFAVGQGAGVYSVGKKYTRGAFRYMTVVSNTTATVSLNSVKINYTASPIQDLRAYTGYFHSSDELLNRIWYAGAYTLQLCSIDPTTGDALVGLGAITSSETITLPQTDKWWTNYTITNGSSTLTDGAKRDRLVWPGDMSIALESVAVSTEDLYSVRTALESLYALQKADGQLPYAGKPFYDMVSFTYHLHSLVGAASYYQYTGDRAWLTRYWGQYKKGVQWALSGVDSTGLANITASADWLRFGMGAHNIEANAILYYVLNDAISLAQSLNDNAPIRNWTATAARIKTVANELLWDDKNGLYTDNETTTLHPQDGNSWAVKANLTLSANQSAIISESLAARWGPYGAPAPEAGATVSPFIGGFELQAHYQAGQPDRALDLLRLQWGFMLDDPRMTNSTFIEGYSTDGSLVYAPYTNRPRVSHAHGWSTGPTSALTIYTAGLRVTGPAGATWLYKPQPGNLTQVEAGFSTRLGSFASSFSRSGGRYQELSFTTPNGTTGSVELGDVSGQLVSEGGVKVQLVGGKASGLQGGKWRLNV.
[0067] SEQ ID NO. 13 (a-L-rhamnosidase mutant L343V):
[0068] MWSSWLLSALLATEALAVPYEEYILAPSSRDLAPASVRQVNGSVTNAAALTGAGGQATFNGVSSVTYDFGINVAGIVSVDVASASSESAFIGVTFTESSMWISNEACDATQDAGLDTPLWFAVGQGAGVYSVGKKYTRGAFRYMTVVSNTTATVSLNSVKINYTASPIQDLRAYTGYFHSSDELLNRIWYAGAYTLQLCSIDPTTGDALVGLGAITSSETITLPQTDKWWTNYTITNGSSTLTDGAKRDRLVWPGDMSIALESVAVSTEDLYSVRTALESLYALQKADGQLPYAGKPFYDTVSFTYHLHSLVGAASYYQYTGDRAWLTRYWGQYKKGVQWALSGVDSTGLANITASADWVRFGMGAHNIEANAILYYVLNDAISLAQSLNDNAPIRNWTATAARIKTVANELLWDDKNGLYTDNETTTLHPQDGNSWAVKANLTLSANQSAIISESLAARWGPYGAPAPEAGATVSPFIGGFELQAHYQAGQPDRALDLLRLQWGFMLDDPRMTNSTFIEGYSTDGSLVYAPYTNRPRVSHAHGWSTGPTSALTIYTAGLRVTGPAGATWLYKPQPGNLTQVEAGFSTRLGSFASSFSRSGGRYQELSFTTPNGTTGSVELGDVSGQLVSEGGVKVQLVGGKASGLQGGKWRLNV.
[0069] Example 4 α-L-Rhamnosidase Mutant Converts Naringin to Prunin
[0070] The mutant T284M crude enzyme solution with improved α-L-rhamnosidase activity and wild type enzyme crude solution were used to catalyze naringin respectively, the concentration of naringin was 50g / L, the mutant T284M was at pH 5, the reaction temperature was 60℃. After 2h of reaction, 1mL of reaction solution was taken in a centrifuge tube, 3 times volume of methanol was added to terminate the catalytic reaction, then the reaction solution was centrifuged at 12000rpm for 2min, the supernatant was extracted and diluted with methanol, then filtered through a 0.22μm organic filter membrane, and HPLC analysis was performed.
[0071] HPLC analysis conditions: the chromatographic column was C18 reversed-phase silica gel separation column (4.6 mm x 250 mm, 5 μm); the mobile phase was: ultrapure water solution (A), methanol (B) and acetonitrile (C), gradient elution program (percentage represents volume fraction, 0-9 min, 62%-15% A, 12%-35% B, 26%-50% C; 9-20 min, 15%-62%, 35%-12% B, 50%-26% C; UV detection wavelength: 283 nm; flow rate 0.8 mL / min; column temperature: 30 °C; injection volume: 20 μL.
[0072] Prepare naringin and naringenin-7-O-glucoside (prunin) standard solutions of 0.1-2.0 mg / mL respectively, detect according to the above conditions, and plot the standard curve with peak area versus concentration as shown in Figures 2-3 .
[0073] The production rates of naringin by different α-L-rhamnosidase are shown in Figure 4 , the production rate of prunin by wild-type a-L-rhamnosidase is 59.55%, the production rate of prunin by L343V is 75.26%, the production rate of prunin by T284M is 87.35%, and the production rate of prunin by F281W is 34.64%. Therefore, the α-L-rhamnosidase mutant T284M has the best effect on the conversion of naringin.
[0074] Example 5 Determination of the enzymatic properties of α-L-rhamnosidase wild type and mutant T284M
[0075] 1. Determination of the optimum pH and pH stability of α-L-rhamnosidase wild type and mutant T284M
[0076] The wild type and mutant T284M enzyme solutions were placed in buffer solutions of different pH values (pH 4.0, 5.0, 6.0, 7.0, 8.0), and the optimum pH was determined according to the enzyme activity determination method; the enzyme activity was determined after 48 h at 25 °C, and the relative activity was calculated based on the enzyme activity under the optimum pH of the two enzymes as 100%, and the pH stability of the enzyme was determined. The results are shown in Figure 5 and 6 .
[0077] From Figure 5It can be seen that at pH=4.0, the relative enzyme activity of mutant T284M is 82.46%, and that of wild type is 74.69%; at pH=5.0, the relative enzyme activity of mutant T284M is 81.29%, and that of wild type is 80.19%; at pH=6.0, the relative enzyme activity of mutant T284M is 74.5%, and that of wild type is 70.14%; at pH=7.0, the relative enzyme activity of mutant T284M is 83.33%, and that of wild type is 44.77%; the optimal pH for both wild type and mutant T284M is 5.0.
[0078] Depend on Figure 6 It can be seen that after being placed in a pH 4.0-8.0 buffer at 25°C for 48 hours, the mutant T284M maintained a relative enzyme activity of >80% within the pH 4.0-5.0 range, and its stability was better than that of the wild type.
[0079] 2. Determination of the optimal temperature and temperature stability of α-L-rhamnosidase wild-type and mutant T284M
[0080] Wild-type and mutant T284M enzyme solutions were placed in different temperatures (50℃, 55℃, 60℃, 65℃, and 70℃), and their optimal temperatures were determined according to enzyme activity assays. Simultaneously, enzyme activity was measured after incubation at different temperatures for 3 hours. Relative activity was calculated with the enzyme activity at its optimal pH condition as 100% to determine the enzyme's temperature stability. Results are as follows: Figure 7 and 8 As shown.
[0081] Depend on Figure 7 It is known that the optimal temperature for both the wild type and the mutant T284M is 60℃. Figure 8 It can be seen that at the optimal temperature (60℃), the relative enzyme activity of mutant T284M is 38.27%, while that of wild type is 28.5%, indicating that mutant T284M is more stable than wild type.
[0082] 3. Kinetic Analysis
[0083] The kinetic properties of wild-type and mutant T284M enzymes were investigated under optimal reaction conditions (pH 5, 60℃). The Michaelis constant (Km) was calculated and compared using the GraphPad Prism 5 program. m ), maximum reaction rate (V) max ) and catalytic constant (K cat The results are shown in Table 2.
[0084] Table 2 Kinetic parameters of wild type and its mutant T284M
[0085]
[0086]
[0087] From the data in Table 2, it can be seen that the kinetic parameters of mutant T284M are significantly different from those of the wild-type enzyme. The K cat value of mutant T284M is 9.99 s -1 , which is 118.4% higher than that of the wild-type enzyme (4.58 s -1 ); thus, the catalytic efficiency (K cat / K m ) of mutant T284M is 756.8 mM -1 · s -1 , which is 195.8% higher than that of the wild-type enzyme (255.9 mM -1 · s -1 ).
[0088] The above-described embodiments are merely preferred modes of the present application and are not intended to limit the scope of the present application. Various modifications and improvements to the technical solutions of the present application made by those of ordinary skill in the art without departing from the design spirit of the present application shall fall within the scope of protection of the present application as defined by the claims.
Claims
1. An α-L-rhamnosidase mutant, characterized in that, Its amino acid sequence is any one of SEQ ID NO.11 to 13.
2. A gene encoding the α-L-rhamnosidase mutant of claim 1.
3. A recombinant vector comprising the gene of claim 2.
4. An engineered bacterium comprising the recombinant vector of claim 3.
5. The engineered bacteria according to claim 4, characterized in that, The engineered strain is Pichia pastoris.
6. The use of the α-L-rhamnosidase mutant of claim 1, the gene of claim 2, the recombinant vector of claim 3, or the recombinant bacteria of claim 4 or 5 in improving the catalytic efficiency of α-L-rhamnosidase.
7. The application according to claim 6, characterized in that, Improving the catalytic efficiency of the α-L-rhamnosidase is to increase the efficiency of the α-L-rhamnosidase in catalyzing the formation of naringin-7-O-glucoside from naringin.
8. The application of the α-L-rhamnosidase mutant of claim 1, the gene of claim 2, the recombinant vector of claim 3, or the recombinant bacteria of claim 4 or 5 in improving the production efficiency of naringenin-7-O-glucoside.
9. A method for improving the production efficiency of naringenin-7-O-glucoside, characterized in that, The process includes using the α-L-rhamnosidase mutant of claim 1 to catalyze the production of naringin-7-O-glucoside from naringin.
10. The method according to claim 9, characterized in that, The catalysis was carried out at a pH of 5 and a reaction temperature of 60°C.
